|Day Low/High||49.63 / 50.11|
|52 Wk Low/High||44.30 / 67.44|
The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...
Nvidia and Mellanox have many common customers, and also a major common competitor in Intel.
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.
David Tepper's Appaloosa LP renews calls for changes at the top.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2019 on Thursday, April 25, 2019.
Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Barclays 2019 Global Healthcare Conference on Wednesday, March 13, 2019, in Miami.
Reiterates Belief that the Proposed Merger with Celgene is Ill-Advised and Not in the Best Interests of Bristol-Myers Stockholders
Bristol-Myers Squibb Company (NYSE:BMY) today filed an investor presentation with the Securities and Exchange Commission (SEC), and the Board of Directors sent an open letter to the Company's shareholders regarding the previously announced definitive...
Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston.
FAANG rallies are fine when breadth is playing along. FAANG rallies that suck the life out of other stocks (breadth) to feed themselves are bearish.
Experts offer their top stock ideas in oncology detection and treatment.
Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement in response to a letter from Starboard Value ("Starboard"): Bristol-Myers Squibb welcomes the opinions of all of its stockholders and will review Starboard's letter and respond...
Celgene shares traded sharply lower Thursday after one of Bristol-Myers Squibb's key investors said it $74 billion takeover bid for the cancer drug specialist was too risky and expensive.
Believes the Proposed Merger with Celgene is Ill-Advised and Not in the Best Interests of Bristol-Myers Stockholders
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has filed definitive proxy materials with the U.
Bristol-Myers Squibb Company (NYSE:BMY) today provided an update on its proposed acquisition of Celgene Corporation (NASDAQ:CELG).
Merck shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration.
Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bristol-Myers Squibb Company (NYSE: BMY) today announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive...
Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019, in New York.
Right now it feels as though everyone sees the obvious resistance and overbought situation.
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
Stocks rose Monday amid another rush of earnings reports this week including Alphabet results due after the bell.
Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.
Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.
Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.
Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.